Related Experiment Videos
Weight gain and antipsychotic medication
1Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
The Journal of Clinical Psychiatry
|May 16, 2000
Summary
Patients on antipsychotic medications are at high risk for obesity. Regular weight monitoring and obesity assessments are crucial for early intervention and managing weight-related health issues in this population.
Area of Science:
- Psychiatry
- Endocrinology
- Public Health
Background:
- Antipsychotic medications are frequently associated with significant weight gain.
- Patients receiving psychotropic agents are at increased risk for overweight and obesity.
- Obesity in this population exacerbates existing health conditions and increases the risk of new comorbidities.
Purpose of the Study:
- To highlight the risks of weight gain in patients treated with antipsychotics.
- To outline recommended monitoring and assessment strategies for obesity in these patients.
- To provide guidance on preventative and management strategies for overweight and obesity.
Main Methods:
- Periodic monitoring of weight changes during medical and psychiatric examinations.
- Obesity assessment including body mass index and waist circumference evaluation.
- Review of medical history for weight-related comorbidities.
Main Results:
- A weight gain of 5 lb (2.3 kg) or more within a 3-year period necessitates preventative strategies.
- Overweight patients unable to lose weight may require a change in antipsychotic medication.
- Treatment plans should incorporate regular monitoring, dietary changes, and physical activity recommendations.
Conclusions:
- Regular weight monitoring and obesity assessment are essential for patients on antipsychotic treatment.
- Proactive interventions, including lifestyle modifications and potential medication adjustments, are vital for managing weight gain.
- Emphasizing the benefits of even modest weight loss can improve patient adherence and outcomes.